Biocon arm bags USFDA approval for Posaconazole Delayed-Release tablets
Bangalore: Biocon Pharma Limited, a subsidiary of Biocon Limited, has recently announced that the company has received approval of its Abbreviated New Drug Application (ANDA) for Posaconazole Delayed-Release tablets from the US Food and Drug Administration (USFDA). This product is indicated for use in the prevention of certain fungal infections in patients with severely weakened immune...
Bangalore: Biocon Pharma Limited, a subsidiary of Biocon Limited, has recently announced that the company has received approval of its Abbreviated New Drug Application (ANDA) for Posaconazole Delayed-Release tablets from the US Food and Drug Administration (USFDA).
This product is indicated for use in the prevention of certain fungal infections in patients with severely weakened immune systems and is available in 100mg strength.
"This approval further adds to Biocon's portfolio of vertically integrated complex drug products," the company said in a BSE filing.
Read also: Biocon arm gets DCGI nod to initiate clinical study for Itolizumab
Biocon Limited is an innovation-led global biopharmaceuticals company headquartered in Bangalore. It has developed and commercialized novel biologics, biosimilars, and complex small molecule APIs in India and several key global markets, as well as generic formulations in the US and Europe.
Read also: Biocon, Tabuk Pharma ink pact to commercialise speciality generic drugs in Middle East
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd